company background image
7OC0 logo

OncoCyte DB:7OC0 Stock Report

Last Price

€0.18

Market Cap

€21.5m

7D

0%

1Y

-98.8%

Updated

22 Oct, 2023

Data

Company Financials +

7OC0 Stock Overview

A precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally.

7OC0 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health3/6
Dividends0/6

OncoCyte Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for OncoCyte
Historical stock prices
Current Share PriceUS$0.18
52 Week HighUS$15.50
52 Week LowUS$2.76
Beta1.53
11 Month Change0%
3 Month Change-94.29%
1 Year Change-98.84%
33 Year Change-99.35%
5 Year Change-99.37%
Change since IPO-99.89%

Recent News & Updates

Recent updates

Shareholder Returns

7OC0DE BiotechsDE Market
7D0%0.8%-2.2%
1Y-98.8%-14.4%13.3%

Return vs Industry: 7OC0 underperformed the German Biotechs industry which returned -23.1% over the past year.

Return vs Market: 7OC0 underperformed the German Market which returned 5.9% over the past year.

Price Volatility

Is 7OC0's price volatile compared to industry and market?
7OC0 volatility
7OC0 Average Weekly Movementn/a
Biotechs Industry Average Movement6.1%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 7OC0's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine 7OC0's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
200976Josh Riggswww.oncocyte.com

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, biopharma, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies.

OncoCyte Corporation Fundamentals Summary

How do OncoCyte's earnings and revenue compare to its market cap?
7OC0 fundamental statistics
Market cap€21.48m
Earnings (TTM)-€16.24m
Revenue (TTM)€1.04m

20.7x

P/S Ratio

-1.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
7OC0 income statement (TTM)
RevenueUS$1.10m
Cost of RevenueUS$1.03m
Gross ProfitUS$75.00k
Other ExpensesUS$17.27m
Earnings-US$17.20m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-2.09
Gross Margin6.81%
Net Profit Margin-1,562.03%
Debt/Equity Ratio0%

How did 7OC0 perform over the long term?

See historical performance and comparison